BLCO vs TARS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BLCO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BLCO and TARS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BLCO and TARS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Full-year 2025 revenue reached roughly $5.1 billion, and the company sells into the structurally growing markets of an aging population, rising myopia and expanding cataract volumes.

Full BLCO guide

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care. Its business is anchored by XDEMVY (lotilaner ophthalmic solution 0.25%), the first and only FDA-approved treatment that directly targets the Demodex mites behind Demodex blepharitis, a common and previously under-treated eyelid condition. The company delivered roughly 400,000 bottles of XDEMVY in 2025 (up from about 163,000 in 2024) and is building a lotilaner-based pipeline that includes TP-04 for ocular rosacea and TP-05 for potential prevention of Lyme disease, with topline data for both expected in the first half of 2027.

Full TARS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BLCO drivers: Margin and EBITDA expansion; Pharmaceuticals and MIEBO ramp.
• TARS drivers: XDEMVY prescription growth; Large, under-penetrated indication.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. For TARS, the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BLCO if you believe its drivers more; TARS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BLCO and TARS guides.

BLCO. BLCO is not yet consistently GAAP-profitable, so investors lean on adjusted EBITDA and revenue growth rather than earnings multiples. Eye-care peers such as Alcon and The Cooper Companies have traded near 18 to 20 times EV/EBITDA, versus a lower multiple for BLCO that reflects the Bausch Health control discount and leverage. Closing that gap depends heavily on the separation resolving and margins continuing to expand.

TARS. As of July 2026 TARS traded near $67 with a market capitalization around $2.9 billion, valuing the company at several times trailing revenue on a still-unprofitable base. That multiple reflects expectations of continued high XDEMVY growth toward the company's stated peak-sales ambitions. The recent short-seller report contributed to share-price volatility and directly challenges the growth and market-size assumptions embedded in the valuation.

Headline figures (approximate, July 2026): BLCO shows revenue (ttm) ~$5.2B, fy2026 revenue guidance ~$5.42B to $5.52B, q1 2026 revenue ~$1.24B (+9% YoY), fy2026 adj. ebitda guidance ~$1.01B to $1.06B; TARS shows revenue (ttm) ~$540M, xdemvy sales (fy2025) ~$451M, q1 2026 revenue ~$162M, fy2026 sales guidance ~$670-700M.

BLCO and TARS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BLCO and TARS exposure against your real portfolio. It is not an investment adviser.